The US Food and Drug
Administration (FDA) has approved
Tanzeum (albiglutide) subcutaneous
injection to improve glycemic
control, along with diet and
exercise, in adults with type 2
diabetes.
As well as imposing a Boxed
Warning on the product, the FDA
is requiring three post-marketing
surveillance studies to assess
paediatric dosing, efficacy and
safety, the risk of medullary thyroid
carcinoma in all patients over a
15 year period and cardiovascular
outcomes for patients with a high
baseline risk of cardiovascular
disease.The above article was sent to subscribers in Pharmacy Daily's issue from 17 Apr 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Apr 14
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.